Clinical trial
BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M
NCT07519395 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 8, 2026
- Completion date
- July 13, 2027
- Enrollment
- 420 (estimated)
- Sites
- 114
Conditions
As the registry lists them; a condition with its own page is linked.